Burden of disease associated with a COPD eosinophilic phenotype
Hector Ortega,1 Jean-Pierre Llanos,2 Marie-Hélène Lafeuille,3 Guillaume Germain,3 Mei Sheng Duh,4 Christopher F Bell,2 Susan R Sama,5 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA; 2Respiratory, US Medical Affairs, GSK Research Triangle Park, NC, USA; 3Gr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-08-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/burden-of-disease-associated-with-a-copd-eosinophilic-phenotype-peer-reviewed-article-COPD |
| _version_ | 1818898279090356224 |
|---|---|
| author | Ortega H Llanos JP Lafeuille MH Germain G Duh MS Bell CF Sama SR Hahn B |
| author_facet | Ortega H Llanos JP Lafeuille MH Germain G Duh MS Bell CF Sama SR Hahn B |
| author_sort | Ortega H |
| collection | DOAJ |
| description | Hector Ortega,1 Jean-Pierre Llanos,2 Marie-Hélène Lafeuille,3 Guillaume Germain,3 Mei Sheng Duh,4 Christopher F Bell,2 Susan R Sama,5 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA; 2Respiratory, US Medical Affairs, GSK Research Triangle Park, NC, USA; 3Groupe d’analyse, Ltée, Montréal, QC, Canada; 4Analysis Group, Inc., Boston, MA, USA; 5Research Department, Reliant Medical Group, Worcester, MA, USA Purpose: Based on blood and sputum samples, up to 40% of patients with COPD have eosinophilic inflammation; however, there is little epidemiology data characterizing the health care burden within this sub-population. Given that COPD-attributable medical costs in the USA are predicted to approach $50 billion by 2020, we analyzed the effect of blood eosinophil counts and exacerbations on health care resource utilization and costs. Patients and methods: This cross-sectional study used electronic medical records and insurance claims data from the Reliant Medical Group (January 2011–December 2015). Eligible patients were ≥40 years of age, continuously enrolled during the year of interest (2012, 2013, 2014, or 2015), had ≥1 COPD-related code in the preceding year, and documented maintenance therapy use. Patients with ≥1 blood eosinophil count recorded were stratified into 2 cohorts: <150 cells/μL and ≥150 cells/μL. Endpoints included demographics, clinical characteristics, health care resource utilization, and costs. The impact of blood eosinophil count and exacerbation patterns on health care resource utilization and costs was assessed with multivariate analyses. Results: On average, 2,832 eligible patients were enrolled annually, of whom ~28% had ≥1 eosinophil count recorded during the year. The ≥150 cells/μL cohort had numerically higher all-cause and COPD-related health care resource utilization and cost each year compared with the <150 cells/μL cohort, but varied by service and year. Among patients with exacerbations, the ≥150 cells/μL cohort exhibited significantly higher COPD-related costs compared with the <150 cells/μL cohort. Conclusion: Blood eosinophil counts may be a useful biomarker for burden of disease in a subgroup of patients with COPD. Keywords: COPD triple therapy, COPD exacerbations, eosinophils, health care resource utilization |
| first_indexed | 2024-12-19T19:29:32Z |
| format | Article |
| id | doaj.art-fcdfff001c564749ba656070edcc6d14 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-19T19:29:32Z |
| publishDate | 2018-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-fcdfff001c564749ba656070edcc6d142022-12-21T20:08:39ZengDove Medical PressInternational Journal of COPD1178-20052018-08-01Volume 132425243339821Burden of disease associated with a COPD eosinophilic phenotypeOrtega HLlanos JPLafeuille MHGermain GDuh MSBell CFSama SRHahn BHector Ortega,1 Jean-Pierre Llanos,2 Marie-Hélène Lafeuille,3 Guillaume Germain,3 Mei Sheng Duh,4 Christopher F Bell,2 Susan R Sama,5 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA; 2Respiratory, US Medical Affairs, GSK Research Triangle Park, NC, USA; 3Groupe d’analyse, Ltée, Montréal, QC, Canada; 4Analysis Group, Inc., Boston, MA, USA; 5Research Department, Reliant Medical Group, Worcester, MA, USA Purpose: Based on blood and sputum samples, up to 40% of patients with COPD have eosinophilic inflammation; however, there is little epidemiology data characterizing the health care burden within this sub-population. Given that COPD-attributable medical costs in the USA are predicted to approach $50 billion by 2020, we analyzed the effect of blood eosinophil counts and exacerbations on health care resource utilization and costs. Patients and methods: This cross-sectional study used electronic medical records and insurance claims data from the Reliant Medical Group (January 2011–December 2015). Eligible patients were ≥40 years of age, continuously enrolled during the year of interest (2012, 2013, 2014, or 2015), had ≥1 COPD-related code in the preceding year, and documented maintenance therapy use. Patients with ≥1 blood eosinophil count recorded were stratified into 2 cohorts: <150 cells/μL and ≥150 cells/μL. Endpoints included demographics, clinical characteristics, health care resource utilization, and costs. The impact of blood eosinophil count and exacerbation patterns on health care resource utilization and costs was assessed with multivariate analyses. Results: On average, 2,832 eligible patients were enrolled annually, of whom ~28% had ≥1 eosinophil count recorded during the year. The ≥150 cells/μL cohort had numerically higher all-cause and COPD-related health care resource utilization and cost each year compared with the <150 cells/μL cohort, but varied by service and year. Among patients with exacerbations, the ≥150 cells/μL cohort exhibited significantly higher COPD-related costs compared with the <150 cells/μL cohort. Conclusion: Blood eosinophil counts may be a useful biomarker for burden of disease in a subgroup of patients with COPD. Keywords: COPD triple therapy, COPD exacerbations, eosinophils, health care resource utilizationhttps://www.dovepress.com/burden-of-disease-associated-with-a-copd-eosinophilic-phenotype-peer-reviewed-article-COPDCOPD triple therapyCOPD exacerbationseosinophilshealthcare resource utilization |
| spellingShingle | Ortega H Llanos JP Lafeuille MH Germain G Duh MS Bell CF Sama SR Hahn B Burden of disease associated with a COPD eosinophilic phenotype International Journal of COPD COPD triple therapy COPD exacerbations eosinophils healthcare resource utilization |
| title | Burden of disease associated with a COPD eosinophilic phenotype |
| title_full | Burden of disease associated with a COPD eosinophilic phenotype |
| title_fullStr | Burden of disease associated with a COPD eosinophilic phenotype |
| title_full_unstemmed | Burden of disease associated with a COPD eosinophilic phenotype |
| title_short | Burden of disease associated with a COPD eosinophilic phenotype |
| title_sort | burden of disease associated with a copd eosinophilic phenotype |
| topic | COPD triple therapy COPD exacerbations eosinophils healthcare resource utilization |
| url | https://www.dovepress.com/burden-of-disease-associated-with-a-copd-eosinophilic-phenotype-peer-reviewed-article-COPD |
| work_keys_str_mv | AT ortegah burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT llanosjp burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT lafeuillemh burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT germaing burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT duhms burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT bellcf burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT samasr burdenofdiseaseassociatedwithacopdeosinophilicphenotype AT hahnb burdenofdiseaseassociatedwithacopdeosinophilicphenotype |